An open label, phase 2 study of biweekly Velcade [bortezomib] and intermittent Caelyx [doxorubicin-liposomal] in patients with ovarian cancer failing platinum containing regimens

Trial Profile

An open label, phase 2 study of biweekly Velcade [bortezomib] and intermittent Caelyx [doxorubicin-liposomal] in patients with ovarian cancer failing platinum containing regimens

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Bortezomib; Doxorubicin liposomal
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 15 Jul 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 05 Oct 2008 Planned end date changed from 1 Sep 2008 to 1 Sep 2009 as reported by ClinicalTrials.gov.
    • 15 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top